An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy

References

• AlamanosYVoulgariPVDrososAAIncidence and prevalence of psoriatic arthritis: a systematic reviewJ Rheumatol20083571354135818464305
   PubMed Web of Science ®Google Scholar
• SorianoERRosaJVelozoEIncidence and prevalence of psoriatic arthritis in Buenos Aires, Argentina: a 6-year health management organization-based studyRheumatology (Oxford)201150472973421134962
   PubMed Web of Science ®Google Scholar
• GladmanDDAntoniCMeasePCleggDONashPPsoriatic arthritis: epidemiology, clinical features, course, and outcomeAnn Rheum Dis200564Suppl 2ii14ii1715708927
   PubMed Web of Science ®Google Scholar
• Torre AlonsoJCRodriguez PerezAArribas CastrilloJMBallina GarciaJRiestra NoriegaJLLopez LarreaCPsoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patientsBr J Rheumatol19913042452501863819
   PubMedGoogle Scholar
• GladmanDDShuckettRRussellMLThorneJCSchachterRKPsoriatic arthritis (PSA) – an analysis of 220 patientsQ J Med1987622381271413659255
   PubMedGoogle Scholar
• OryPAGladmanDDMeasePJPsoriatic arthritis and imagingAnn Rheum Dis200564Suppl 2ii55ii5715708938
   PubMed Web of Science ®Google Scholar
• SiannisFFarewellVTCookRJSchentagCTGladmanDDClinical and radiological damage in psoriatic arthritisAnn Rheum Dis200665447848116126794
   PubMed Web of Science ®Google Scholar
• RosenCFMussaniFChandranVEderLThavaneswaranAGladmanDDPatients with psoriatic arthritis have worse quality of life than those with psoriasis aloneRheumatology (Oxford)201251357157622157469
   PubMed Web of Science ®Google Scholar
• HustedJAGladmanDDFarewellVTLongJACookRJValidating the SF-36 health survey questionnaire in patients with psoriatic arthritisJ Rheumatol19972435115179058658
   PubMed Web of Science ®Google Scholar
• HustedJAGladmanDDFarewellVTCookRJHealth-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritisArthritis Rheum200145215115811324779
   PubMed Web of Science ®Google Scholar
• HansenRBKavanaughACertolizumab pegol for the treatment of psoriatic arthritisExpert Rev Clin Immunol201511330731825651776
   PubMed Web of Science ®Google Scholar
• GossecLSmolenJSGaujoux-VialaCEuropean League against rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapiesAnn Rheum Dis201271141221953336
   PubMed Web of Science ®Google Scholar
• CostaLCasoFRamondaRMetabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational studyImmunol Res2015611–214715325395342
   PubMed Web of Science ®Google Scholar
• EderLThavaneswaranAChandranVCookRJGladmanDDObesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritisAnn Rheum Dis201574581381724431392
   PubMed Web of Science ®Google Scholar
• CostaLCasoFAttenoMImpact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patientsClin Rheumatol201433683383923959447
   PubMed Web of Science ®Google Scholar
• SorianoERAcosta-FelquerMLLuongPCaplanLPharmacologic treatment of psoriatic arthritis and axial spondyloarthritis with traditional biologic and non-biologic DMARDsBest Practice Res Clin Rheumatol2014285793806
   Web of Science ®Google Scholar
• GladmanDDEarly psoriatic arthritisRheum Dis Clin North Am201238237338622819090
   PubMed Web of Science ®Google Scholar
• Acosta FelquerMLFerreyra GarrottLMarinJRemission criteria and activity indices in psoriatic arthritisClin Rheumatol20143391323133024820142
   PubMed Web of Science ®Google Scholar
• GladmanDDMeasePJStrandVConsensus on a core set of domains for psoriatic arthritisJ Rheumatol20073451167117017477480
   PubMed Web of Science ®Google Scholar
• SchoelsMMBraunJDougadosMTreating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritisAnn Rheum Dis201473123824223740234
   PubMed Web of Science ®Google Scholar
• SorianoERTreatment guidelines for psoriatic arthritisInt J Clin Rheumatol20094329342
   Google Scholar
• CasoFCostaLDel PuenteAPharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapiesTher Adv Chronic Dis20156632833826568809
   PubMed Web of Science ®Google Scholar
• CoatesLCKavanaughAMeasePJGroup for research and assessment of psoriasis and psoriatic arthritis: Treatment recommendations for psoriatic arthritis 2015Arthritis Rheumatol Epub201618
   Web of Science ®Google Scholar
• SorianoERThe actual role of therapy with traditional disease- modifying antirheumatic drugs in psoriatic arthritisJ Rheumatol Suppl201289677022751597
   PubMedGoogle Scholar
• MeasePJGoffeBSMetzJVanderStoepAFinckBBurgeDJEtanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trialLancet2000356922738539010972371
   PubMed Web of Science ®Google Scholar
• MeasePJGladmanDDRitchlinCTAdalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trialArthritis Rheum200552103279328916200601
   PubMed Web of Science ®Google Scholar
• MeasePJFleischmannRDeodharAAEffect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)Ann Rheum Dis2014731485523942868
   PubMed Web of Science ®Google Scholar
• AntoniCEKavanaughAvan der HeijdeDTwo-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)J Rheumatol200835586987618381786
   PubMed Web of Science ®Google Scholar
• KavanaughAMcInnesIMeasePGolimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled studyArthritis Rheum200960497698619333944
   PubMed Web of Science ®Google Scholar
• Delgado FriasEDiaz GonzalezJFCertolizumab pegolRheumatol Clin20116S3S7S11 Spanish
   Google Scholar
• ChimentiMSSaracenoRChiricozziAGiuntaAChimentiSPerriconeRProfile of certolizumab and its potential in the treatment of psoriatic arthritisDrug Des Devel Ther20137339348
   PubMed Web of Science ®Google Scholar
• FelquerMLSorianoERNew treatment paradigms in psoriatic arthritis: an update on new therapeutics approved by the U.S. Food and Drug AdministrationCurr Opinion Rheumatol201527299106
   PubMed Web of Science ®Google Scholar
• CasoFLubranoEDel PuenteAProgress in understanding and utilizing TNF-alpha inhibition for the treatment of psoriatic arthritisExpert Rev Clin Immunol2015117
   Web of Science ®Google Scholar
• NesbittAFossatiGBerginMMechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agentsInflamm Bowel Dis200713111323133217636564
   PubMed Web of Science ®Google Scholar
• LugeringASchmidtMLugeringNPauelsHGDomschkeWKucharzikTInfliximab induces apoptosis in monocytes from patients with chronic active Crohn’s disease by using a caspase-dependent pathwayGastroenterology200112151145115711677207
   PubMed Web of Science ®Google Scholar
• ShenCAsscheGVColpaertSAdalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanerceptAliment Pharmacol Ther200521325125815691299
   PubMed Web of Science ®Google Scholar
• RosaJSabelliMSorianoERPrefilled certolizumab pegol (Cimzia((®))) syringes for self-use in the treatment of rheumatoid arthritisMed Devices (Auckl)20103253122915918
   PubMedGoogle Scholar
• DhillonSCertolizumab pegol: a review of its use in patients with axial spondyloarthritis or psoriatic arthritisDrugs2014749999101624919863
   PubMed Web of Science ®Google Scholar
• GladmanDFleischmannRCoteurGWolteringFMeasePJEffect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter studyArthritis Care Res (Hoboken)20146671085109224339179
   PubMed Web of Science ®Google Scholar
• MeasePFleischmannRWollenhauptJEffect of certolizumab pegol over 48 weeks on signs and symptoms in patients with psoriatic arthritis with and without prior tumor necrosis factor inhibitor exposureArthritis Rheum201365SupplS132
   Google Scholar
• TillettWde-VriesCMcHughNJWork disability in psoriatic arthritis: a systematic reviewRheumatology (Oxford)201251227528321752872
   PubMed Web of Science ®Google Scholar
• MeasePJMenterMAQuality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspectiveJ Am Acad Dermatol200654468570416546593
   PubMed Web of Science ®Google Scholar
• KavanaughAGladmanDvan der HeijdeDPurcaruOMeasePImprovements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled studyAnn Rheum Dis2015741445124942382
   PubMed Web of Science ®Google Scholar
• van der HeijdeDFleischmannRWollenhauptJEffect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certoli-zumab pegolAnn Rheum Dis201473123323723942869
   PubMed Web of Science ®Google Scholar
• LandewéRBraunJDeodharAEfficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 studyAnn Rheum Dis2014731394724013647
   PubMed Web of Science ®Google Scholar
• NashPLubranoECauliATaylorWJOlivieriIGladmanDDUpdated guidelines for the management of axial disease in psoriatic arthritisJ Rheumatol201441112286228925362712
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyAnnex 1: summary of product characteristics (Cimzia) Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001037/WC500069763.pdfwww.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001037/WC500069763.pdfAccessed October 18, 2014
   Google Scholar
• MahadevanUWolfDCDubinskyMPlacental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel diseaseClin Gastroenterol Hepatol2013113286292 quiz e22423200982
   PubMed Web of Science ®Google Scholar
• ClowseMEWolfDCForgerFPregnancy outcomes in subjects exposed to certolizumab pegolJ Rheumatol201542122270227826523031
   PubMed Web of Science ®Google Scholar
• WakefieldIStephensSFoulkesRNesbittABourneTThe use of surrogate antibodies to evaluate the developmental and reproductive toxicity potential of an anti-TNFalpha PEGylated Fab’ monoclonal antibodyToxicol Sci2011122117017621507990
   PubMed Web of Science ®Google Scholar
• MarchioniRMLichtensteinGRTumor necrosis factor-alpha inhibitor therapy and fetal risk: a systematic literature reviewWorld J Gastroenterol201319172591260223674866
   PubMed Web of Science ®Google Scholar
• Remicade (infliximab) prescribing information2013 Available from: http://www.remicade.com/shared/product/remicade/prescribing-information.pdfAccessed March 10, 2016
   Google Scholar
• Humira (adalimumab) prescribing information2014 Available from: http://www.rxabbvie.com/pdf/humira.pdfAccessed March 10, 2016
   Google Scholar
• TakeuchiTYamamotoKYamanakaHPost-hoc analysis showing better clinical response with the loading dose of Certolizumab pegol in Japanese patients with active rheumatoid arthritisMod Rheumatol2015126
   Google Scholar
• YamamotoKTakeuchiTYamanakaHEfficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trialMod Rheumatol201424571572424313916
   PubMed Web of Science ®Google Scholar
• YamamotoKTakeuchiTYamanakaHEfficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trialMod Rheumatol201424455256024981319
   PubMed Web of Science ®Google Scholar